Estimation of the prevalence of attention deficit disorder with or without hyperactivity under methylphenidate treatment in Asturias (Spain) through consumption of the active ingredient from 2002 to 2010

Downloads

Published

2012-03-30

How to Cite

Fernández Pérez, M., & Iglesias Carbajo, A. I. (2012). Estimation of the prevalence of attention deficit disorder with or without hyperactivity under methylphenidate treatment in Asturias (Spain) through consumption of the active ingredient from 2002 to 2010. Revista De Psiquiatría Infanto-Juvenil, 29(1), 42–49. Retrieved from https://aepnya.eu/index.php/revistaaepnya/article/view/240

Issue

Vol. 29 No. 1 (2012)

Section

Orginial article

Authors

  • M Fernández Pérez Área Sanitaria VIII de Asturias, Centro de Salud de La Felguera
  • A I Iglesias Carbajo Área Sanitaria VIII de Asturias, Centro de Salud de La Felguera

Keywords:

Daily dose per inhabitant, pharmacoepidemology, methylphenidate, attention deficit hyperactivity disorder, prevalence, variability

Abstract

Introduction. The consumption of methylphenidate can be used to estimate the prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in pharmacological treatment, thus the minimum prevalence of the disorder. For this to be calculated, we need to know the daily doses of methylphenidate per 1000 inhabitants per day, which is obtained out of the relation between the number of daily defined doses (DDD) and the target population. The goal was to know the treated ADHD’s prevalence amongst population of children up to fourteen years old and particularly population of children from 6 to 14 in the Autonomous Community of the Principality of Asturias (Spain), both globally and in the different Sanitary Areas. Material and methods. We had the records of the consumption of methylphenidate, in its different preparations, in Asturias from 2002 through 2010. At our disposal, as well as information about pediatric cohorts (0-14 years from 2002 at 2010 on and 6-14 years in 2010’s test) of all Sanitary Areas with the purpose of calculating the daily doses of methylphenidate per 1000 inhabitants per day in the aforesaid populations. Results. The prevalence of the treated ADHD in Asturias by 2010 was of 4.111 per 1,000 inhabitants, which represents 0.41% of the child population. Amongst the population from 6 to 14 years, in 2010 the prevalence was of 0.73%. The Sanitary Area of Langreo obtained the highest daily doses of methylphenidate per 1000 inhabitants per day in 2010’s test, with a percentage of 0.69% (6.900 per 1,000 inhabitants) of prevalence amongst child population, whereas the population from 6 to 14 years had a 1.24%. We objectify a continued growth for prevalence figures, but with an important variability in the Sanitary Areas. Conclusions. In relation with the published Spanish prevalence figures, which range from 5 and 6%, the found prevalence in our population is lower. We discuss the reason of this discrepancy and we compare with the data of countries within our socioeconomic environment.

Downloads

Download data is not yet available.

Author Biographies

M Fernández Pérez, Área Sanitaria VIII de Asturias, Centro de Salud de La Felguera

Pediatra, Psicólogo. 

A I Iglesias Carbajo, Área Sanitaria VIII de Asturias, Centro de Salud de La Felguera

Farmacéutica. Gerencia de Atención Primaria, Área Sanitaria VIII de Asturias. Centro de Salud de La Felguera, Asturias

References

1. Cardo E, Servera M, Llobera J. Estimación de la prevalencia del trastorno por déficit de atención e hiperactividad en población normal de la isla de Mallorca. Rev Neurol 2007;44:10-4.

2. Rodríguez L, López JA, Garrido M, Sacristán AM, Martínez MT, Ruiz F. Estudio psicométrico-clínico de prevalencia y comorbilidad del trastorno por déficit de atención con hiperactividad en Castilla y León (España). Rev Pediatr Aten Primaria 2009;11:251-70.
3. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/ DDD/Index) 2011: methylphenidate. En: http:// www.whocc.no/atc_ddd_index/. Acceso on-line el 11-01-2011.

4. Sistema de codificación de principios activos y Dosis Diarias Definidas del INSALUD. 2ª edición, Madrid, 2002.

5. Criado Alvarez JJ, Romo Barrientos C. Variabilidad y tendencias en el consumo de metilfenidato en España. Estimación de la prevalencia del Trastorno por Déficit de Atención con Hiperactividad. Rev Neurol 2003;37:806-10.

6. Macipe Costa R, Gimeno Feliu LA, Armesto FJ, Magallón Botaya R y García-Campayo J. C-20. Diferencias de consumo de metilfenidato entre la población infantil autóctona e inmigrante de Aragón. Rev Pediatr Aten Primaria 2009;11: e24-e25. Acceso el 11-01-2011.

7. Knellwolf AL, Deligne J, Chiarotti F, Auley GR, Palmeri S, Boisgard CB, Panei P, Autret-Leca E. Prevalence and patterns of methylphenidate use in Fench children and adolescents. Europ J Clin Pharmacol 2008;64:311-7.

8. Jick H, Kaye JA, Black C. Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK. Br J Gen Pract 2004;54:345-7.

9. Schubert I, Köster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Dtsch Arztebl Int 2010;107:615-21.

10. Asheim H, Nilsen KB, Johansen K, Furu K. Prescribing of stimulants for ADHD in Nordland County. Tidsskr Nor Laegeforen 2007;127:2360- 2.

11. Doncker GA, Groenhof F, van der Veen WJ. Increasing trend in prescription of methylphenidate in general practices in the north-east of The Netherlands, 1998-2003. Ned Tijdschr Geneeskd 2005;149:1742-7.

12. Zoëga H, Baldursson G, Halldórsson M. Use of methylphenidate among children in Iceland 1989- 2006. Laeknabladid 2007;93:825-32.

13. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006;163:579-85.

14. Miller AR, Brehaut JC, Raina P, McGrail KM, Armstrong RW. Use of medical services by methylphenidate- treated children in the general population. Ambul Pediatr 2004;4:174-80.

15. Sawyer MG, Rey JM, Graetz BW, Clark JJ, Baghurst PA. Use of medication by young people with attention-deficit/hyperactivity disorder. Med J Aust 2002;177:21-5.

16. Vinker S, Vinker R, Elhayany A. Prevalence of methylphenidate use among Israeli children: 1998-2004. Clin Drug Investig 2006;26:161-7.

17. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics 1996;98:1084-8.

18. Charach A, Cao H, Schachar R, To T. Correlates of methylphenidate use in Canadian children: a crosssectional study. Can J Psychiatry 2006;51:17-26.

19. Robison LM, Skaer TL, Sclar DA, Galin RS. Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 2002;16:129-37.

20. Winterstein AG, Gerhard T, Shuster J, Zito J, Jhonson M, Liu H, Saidi A. Utilization of pharmacologic treatment in youths with attention-deficit/ hyperactivity disorder in Medicaid database. Ann Pharmacother 2008;42:24-31.

21. Romano E, Thornhill S, Lacourse E. An 8-year follow-up of profiles and predictors of methylphenidate use in a natioanlwide sample of boys. J Pediatr 2009;155:721-7.

22. Gumy C, Huissoud T, Dubois-Arber F. Prevalence of methylphenidate prescription among schoolaged children in a Swiss population: increase in the number of prescriptions in the Swiss Canton of Vaud, from 2002 to 2005, and changes in patient demographics. J Atten Disord 2010;14:267-72.

23. Fogelman Y, Kahan E. Methylphenidate use for attention deficit hyperactivity disorder in northern Israel -a controversial issue. Isr Med Assoc J 2001;3:925-7.

24. Fogelman Y, Vinker S, Guy N, Kahan E. Prevalence of and change in the prescription of methylphenidate in Israel over a 2-year period. CNS Drugs 2003;17:915-9.

25. Safer DJ. Are stimulants overprescribed for youths with ADHD?. Ann Clin Psychiatry 2000;12:55-62.

26. PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, Hoven C, Bird HR, Bauermeister JJ, Payne JD. Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry 1999;38:797-804.